Literature DB >> 10724795

Economic evaluation of long-term management strategies for erosive oesophagitis.

R Goeree1, B O'Brien, R Hunt, G Blackhouse, A Willan, J Watson.   

Abstract

OBJECTIVE: To compare the expected costs and outcomes of alternative strategies for the management of patients with erosive oesophagitis.
DESIGN: There were 3 components to the overall analytic approach. First, a decision model was constructed to compare expected costs and outcomes of 6 management strategies. Second, principles of quantitative literature review and meta-analysis were used to determine probabilities of clinical events (i.e. oesophagitis healing and recurrence). Finally, principles of cost-effectiveness analysis were used to compare treatment alternatives in terms of dominance and incremental cost effectiveness. The viewpoint for the study was that of a provincial government payer for healthcare over a 1-year period. MAIN OUTCOME MEASURES AND
RESULTS: Healing rates were significantly higher for proton pump inhibitors (PPI) [p < 0.001]. Recurrence rates were significantly higher for intermittent therapy (placebo) and lower for regular dose PPI (p < 0.001). Maintenance prokinetic agent (PA) is dominated (i.e. more costly and less effective) and step-down maintenance PPI is dominated through principles of extended dominance. The 'efficient frontier' is represented by: maintenance H2-receptor antagonist (H2RA), intermittent PPI, step-down maintenance H2RA and maintenance PPI.
CONCLUSIONS: The price of H2RA is a key factor influencing whether step-down maintenance PPI forms part of, or is contained within, the 'efficient frontier' of long term management for erosive oesophagitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10724795     DOI: 10.2165/00019053-199916060-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  82 in total

1.  Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis.

Authors:  B J Biggerstaff; R L Tweedie
Journal:  Stat Med       Date:  1997-04-15       Impact factor: 2.373

2.  Cisapride and cimetidine in the treatment of erosive esophagitis.

Authors:  A Maleev; A Mendizova; P Popov; V Vlahov; B Dimitrov; A Mihova; J Crowe; J Silveira; A Thomson; G Routhier
Journal:  Hepatogastroenterology       Date:  1990-08

3.  Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.

Authors:  S J Sontag; D G Kogut; R Fleischmann; D R Campbell; J Richter; M Robinson; M McFarland; S Sabesin; G A Lehman; D Castell
Journal:  Am J Gastroenterol       Date:  1997-03       Impact factor: 10.864

4.  Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis.

Authors:  F Pace; O Sangaletti; G Bianchi Porro
Journal:  Ital J Gastroenterol       Date:  1990-02

5.  Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study.

Authors:  J E Richter; J F Long
Journal:  Am J Gastroenterol       Date:  1995-03       Impact factor: 10.864

6.  Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.

Authors:  A L Gough; R G Long; B T Cooper; C S Fosters; A D Garrett; C H Langworthy
Journal:  Aliment Pharmacol Ther       Date:  1996-08       Impact factor: 8.171

7.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

8.  A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial.

Authors:  J Mössner; A H Hölscher; R Herz; A Schneider
Journal:  Aliment Pharmacol Ther       Date:  1995-06       Impact factor: 8.171

9.  Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis.

Authors:  E Masci; P A Testoni; S Passaretti; M Guslandi; A Tittobello
Journal:  Drugs Exp Clin Res       Date:  1985

10.  Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.

Authors:  M Robinson; F Lanza; D Avner; M Haber
Journal:  Ann Intern Med       Date:  1996-05-15       Impact factor: 25.391

View more
  9 in total

1.  The importance of the comparator in economic evaluations: working on the efficiency frontier.

Authors:  Mattias Neyt; Hans Van Brabandt
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

Review 3.  Efficiency of potent gastric acid inhibition.

Authors:  Fernando Carballo
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK.

Authors:  Peter Wahlqvist; Ola Junghard; Andy Higgins; Jonathan Green
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  A one-year economic evaluation of six alternative strategies in the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care.

Authors:  Alan N Barkun; Ralph Crott; Carlo A Fallone; Wendy A Kennedy; Jean Lachaine; Carey Levinton; David Armstrong; Naoki Chiba; Alan Thomson; Sander Veldhuyzen van Zanten; Paul Sinclair; Sergio Escobedo; Bijan Chakraborty; Sandra Smyth; Robert White; Helen Kalra; Krista Nevin
Journal:  Can J Gastroenterol       Date:  2010-08       Impact factor: 3.522

6.  Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease.

Authors:  Dyfrig A Hughes; Keith Bodger; Peter Bytzer; Dirk de Herdt; Dominique Dubois
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 7.  On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations.

Authors:  John M Inadomi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  Sensitivity to Excluding Treatments in Network Meta-analysis.

Authors:  Lifeng Lin; Haitao Chu; James S Hodges
Journal:  Epidemiology       Date:  2016-07       Impact factor: 4.822

9.  Economic impact of potentially inappropriate prescribing and related adverse events in older people: a cost-utility analysis using Markov models.

Authors:  Frank Moriarty; Caitriona Cahir; Kathleen Bennett; Tom Fahey
Journal:  BMJ Open       Date:  2019-01-30       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.